Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print May 29, 2003, 10.1148/radiol.2281011303
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2281011303v1
228/1/63    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delille, J.-P.
Right arrow Articles by Garrido, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delille, J.-P.
Right arrow Articles by Garrido, L.
(Radiology 2003;228:63-69.)
© RSNA, 2003

Breast Imaging

Invasive Ductal Breast Carcinoma Response to Neoadjuvant Chemotherapy: Noninvasive Monitoring with Functional MR Imaging— Pilot Study1

Jean-Paul Delille, MD, Priscilla J. Slanetz, MD, MPH, Eren D. Yeh, MD, Elkan F. Halpern, PhD, Daniel B. Kopans, MD and Leoncio Garrido, PhD

1 From the NMR Center (J.P.D., L.G.) and Division of Breast Imaging (E.D.Y., E.F.H., D.B.K.), Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Mass; and Division of Breast Imaging, Department of Radiology, Saint Elizabeth’s Medical Center, 736 Cambridge St, Brighton, MA 02135 (P.J.S.). From the 2000 RSNA scientific assembly. Received July 31, 2001; revision requested September 24; final revision received October 18, 2002; accepted November 5. Supported by the Association pour la Recherche contre le Cancer, Société Française de Radiologie, Institut National de la Santé et de la Recherche Médicale, Massachusetts General Hospital-NMR Center, and RSNA Research and Education Foundation. Address correspondence to P.J.S. (e-mail: priscilla_slanetz@cchcs.org).

PURPOSE: To investigate if the extraction flow product (EFP), as determined on dynamic contrast material–enhanced magnetic resonance (MR) images, could be a potential marker of tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

MATERIALS AND METHODS: Fourteen women with proven breast cancer underwent MR imaging prior to and following neoadjuvant chemotherapy. Dynamic gradient-echo and echo-planar MR images were acquired before and after injection of gadopentetate dimeglumine. Precontrast T1s were measured before EFP maps were calculated by using a multicompartmental model. Mean EFP (EFPmean) and distribution analysis of EFP (EFPcount) were measured in tumors before and after neoadjuvant chemotherapy and were compared with tumor response at MR imaging. The significance of the difference in EFP values between the responders and nonresponders was calculated with a two-tailed Student t test.

RESULTS: EFPmean after neoadjuvant chemotherapy in partial responders and nonresponders was 33 mL · 100 g-1 · min-1 ± 9.8 and 54.2 mL · 100 g-1 · min-1 ± 10.3, respectively (P < .005). EFPmean decreased after neoadjuvant chemotherapy in the responders and nonresponders by 37% ± 30 and -5% ± 35, respectively (P > .05). An increase in EFPmean values was observed only in nonresponders who received taxanes. For regimens without taxanes, EFPmean decreased regardless of the morphologic response. EFPcount decreased for all the responders by 77% ± 33 and increased for all the nonresponders by 45% ± 68 (P < .02).

CONCLUSION: EFPcount appears to provide functional information regarding changes in tumor angiogenesis due to neoadjuvant chemotherapy. Functional MR imaging of the breast may be useful in monitoring tumor response to neoadjuvant chemotherapy.

© RSNA, 2003

Index terms: Breast neoplasms, 00.321, 00.327 • Breast neoplasms, MR, 00.121412, 00.121413, 00.121416, 00.12143, 00.12146 • Chemotherapy • Magnetic resonance (MR), diffusion study, 00.12144 • Magnetic resonance (MR), tissue characterization, 00.12144, 00.12146




This article has been cited by other articles:


Home page
 RadiologyHome page
C. K. Kuhl
Current Status of Breast MR Imaging * Part 2. Clinical Applications
Radiology, September 1, 2007; 244(3): 672 - 691.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
E. Yeh, P. Slanetz, D. B. Kopans, E. Rafferty, D. Georgian-Smith, L. Moy, E. Halpern, R. Moore, I. Kuter, and A. Taghian
Prospective Comparison of Mammography, Sonography, and MRI in Patients Undergoing Neoadjuvant Chemotherapy for Palpable Breast Cancer
Am. J. Roentgenol., March 1, 2005; 184(3): 868 - 877.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. C. Miller, H. H. Pien, D. Sahani, A. G. Sorensen, and J. H. Thrall
Imaging Angiogenesis: Applications and Potential for Drug Development
J Natl Cancer Inst, February 2, 2005; 97(3): 172 - 187.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
S. Meisamy, P. J. Bolan, E. H. Baker, R. L. Bliss, E. Gulbahce, L. I. Everson, M. T. Nelson, T. H. Emory, T. M. Tuttle, D. Yee, et al.
Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vivo 1H MR Spectroscopy--A Pilot Study at 4 T
Radiology, November 1, 2004; 233(2): 424 - 431.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2003 by the Radiological Society of North America.